Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab.

Najjar YG, Ding F, Lin Y, VanderWeele R, Butterfield LH, Tarhini AA.

J Transl Med. 2017 Feb 21;15(1):39. doi: 10.1186/s12967-017-1140-9.

2.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

3.

Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.

Retseck J, VanderWeele R, Lin HM, Lin Y, Butterfield LH, Tarhini AA.

J Immunother Cancer. 2016 Jun 21;4:38. doi: 10.1186/s40425-016-0141-1. eCollection 2016.

4.

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):632-46. doi: 10.1016/j.ijrobp.2016.01.038. Review.

5.

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients.

Mehta K, Appleman L, Wang H, Tarhini AA, Parikh RA.

PLoS One. 2016 Jan 22;11(1):e0147153. doi: 10.1371/journal.pone.0147153. eCollection 2016.

6.

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.

Tarhini AA, Zahoor H, Yearley JH, Gibson C, Rahman Z, Dubner R, Rao UN, Sander C, Kirkwood JM.

J Transl Med. 2015 Sep 30;13:319. doi: 10.1186/s12967-015-0678-7.

7.

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.

Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, Kirkwood JM.

J Immunother Cancer. 2015 Sep 15;3:39. doi: 10.1186/s40425-015-0081-1. eCollection 2015.

9.

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.

Floros T, Tarhini AA.

Semin Oncol. 2015 Aug;42(4):539-48. doi: 10.1053/j.seminoncol.2015.05.015. Epub 2015 Jun 3. Review.

10.

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients.

Tarhini AA, Lin Y, Zahoor H, Shuai Y, Butterfield LH, Ringquist S, Gogas H, Sander C, Lee S, Agarwala SS, Kirwood JM.

PLoS One. 2015 Jul 20;10(7):e0132745. doi: 10.1371/journal.pone.0132745. eCollection 2015.

11.

Immune checkpoint blockade and interferon-α in melanoma.

Rafique I, Kirkwood JM, Tarhini AA.

Semin Oncol. 2015 Jun;42(3):436-47. doi: 10.1053/j.seminoncol.2015.02.012. Epub 2015 Feb 14. Review.

12.

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.

Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM.

JAMA. 2014 Nov 5;312(17):1744-53. doi: 10.1001/jama.2014.13943.

13.

Surviving with lung cancer: medication-taking and oral targeted therapy.

Wickersham KE, Happ MB, Bender CM, Engberg SJ, Tarhini A, Erlen JA.

Geriatr Nurs. 2014 Mar-Apr;35(2 Suppl):S49-56. doi: 10.1016/j.gerinurse.2014.02.020.

14.

Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa.

Tarhini AA, Shin D, Lee SJ, Stuckert J, Sander CA, Kirkwood JM.

Melanoma Res. 2014 Apr;24(2):150-7. doi: 10.1097/CMR.0000000000000050.

15.

Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.

Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, Rao UN, Kirkwood JM.

PLoS One. 2014 Feb 3;9(2):e87705. doi: 10.1371/journal.pone.0087705. eCollection 2014.

16.

A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma.

Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, Lee S, Kirkwood JM.

J Transl Med. 2014 Jan 23;12:19. doi: 10.1186/1479-5876-12-19.

17.

PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.

Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, Wang H, Guillaume P, Luescher IF, Krieg A, Anderson AC, Kuchroo VK, Zarour HM.

Cancer Res. 2014 Feb 15;74(4):1045-55. doi: 10.1158/0008-5472.CAN-13-2908. Epub 2013 Dec 16.

18.

Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.

Tarhini A.

Scientifica (Cairo). 2013;2013:857519. doi: 10.1155/2013/857519. Epub 2013 Apr 17. Review.

19.

Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.

Tarhini AA, Zahoor H, McLaughlin B, Gooding WE, Schmitz JC, Siegfried JM, Socinski MA, Argiris A.

Anticancer Res. 2013 Oct;33(10):4475-81.

20.

ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).

Go RS, Lee SJ, Shin D, Callister SM, Jobe DA, Conry RM, Tarhini AA, Kirkwood JM.

Clin Cancer Res. 2013 Dec 1;19(23):6597-604. doi: 10.1158/1078-0432.CCR-13-1414. Epub 2013 Oct 11.

Supplemental Content

Loading ...
Support Center